Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2017 Dec 14;130(24):2682-2688.
doi: 10.1182/blood-2017-07-798660. Epub 2017 Oct 3.

Hematopoietic stem cell transplantation rescues the hematological, immunological, and vascular phenotype in DADA2

Affiliations
Multicenter Study

Hematopoietic stem cell transplantation rescues the hematological, immunological, and vascular phenotype in DADA2

Hasan Hashem et al. Blood. .

Abstract

Deficiency of adenosine deaminase 2 (DADA2) is caused by biallelic deleterious mutations in CECR1 DADA2 results in variable autoinflammation and vasculopathy (recurrent fevers, livedo reticularis, polyarteritis nodosa, lacunar ischemic strokes, and intracranial hemorrhages), immunodeficiency and bone marrow failure. Tumor necrosis factor-α blockade is the treatment of choice for the autoinflammation and vascular manifestations. Hematopoietic stem cell transplantation (HSCT) represents a potential definitive treatment. We present a cohort of 14 patients from 6 countries who received HSCT for DADA2. Indication for HSCT was bone marrow dysfunction or immunodeficiency. Six of 14 patients had vasculitis pre-HSCT. The median age at HSCT was 7.5 years. Conditioning regimens were myeloablative (9) and reduced intensity (5). Donors were HLA-matched sibling (n = 1), HLA-matched unrelated (n = 9), HLA-mismatched unrelated (n = 3), and HLA haploidentical sibling (n = 1). All patients are alive and well with no new vascular events and resolution of hematological and immunological phenotype at a median follow-up of 18 months (range, 5 months to 13 years). Plasma ADA2 enzyme activity normalized in those tested post-HSCT (7/7), as early as day +14 (myeloid engraftment). Post-HSCT hematological autoimmunity (cytopenias) was reported in 4 patients, acute graft-versus-host disease grade 1 in 2, grade 2 in 3, and grade 3-4 in 1, and moderate chronic graft-versus-host disease in 1 patient. In conclusion, in 14 patients, HSCT was an effective and definitive treatment of DADA2.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Figures

Figure 1.
Figure 1.
Effect of HSCT in clinical features resolution. Dark gray squares represent the presence of a clinical feature/phenotype. Light gray squares represent major improvement in clinical features. White squares represent complete resolution of clinical feature. Each patient is presented by 2 attached columns (before and after transplant) for comparison. Follow-up time post-HSCT for each patient is shown in months (first row). Severe infections represent any viral, bacterial, or fungal infection that required antiviral or antifungal treatment or led to sepsis. FTT, failure to thrive.

Comment in

  • HSCT cures ADA2 deficiency.
    Debatin KM. Debatin KM. Blood. 2017 Dec 14;130(24):2582-2583. doi: 10.1182/blood-2017-10-811125. Blood. 2017. PMID: 29242208 No abstract available.

References

    1. Zhou Q, Yang D, Ombrello AK, et al. Early-onset stroke and vasculopathy associated with mutations in ADA2. N Engl J Med. 2014;370(10):911-920. - PMC - PubMed
    1. Navon Elkan P, Pierce SB, Segel R, et al. Mutant adenosine deaminase 2 in a polyarteritis nodosa vasculopathy. N Engl J Med. 2014;370(10):921-931. - PubMed
    1. Caorsi R, Penco F, Schena F, Gattorno M. Monogenic polyarteritis: the lesson of ADA2 deficiency. Pediatr Rheumatol Online J. 2016;14(1):51. - PMC - PubMed
    1. Giannelou A, Zhou Q, Kastner DL. When less is more: primary immunodeficiency with an autoinflammatory kick. Curr Opin Allergy Clin Immunol. 2014;14(6):491-500. - PMC - PubMed
    1. Ben-Ami T, Revel-Vilk S, Brooks R, et al. Extending the clinical phenotype of adenosine deaminase 2 deficiency. J Pediatr. 2016;177:316-320. - PubMed

Publication types

MeSH terms

Substances